Free tool
FAERS Monitor: Benzamycin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050557 or its brand name (Benzamycin, Benzoyl Peroxide, Erythromycin). Reports on generic versions are filed under their own applications.
Reports
162
Serious
83
51% of reports
Hospitalization
31
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective19
- inflammatory bowel disease18
- colitis ulcerative15
- depression14
- anxiety11
- product physical consistency issue11
- colitis10
- rash10
- crohn^s disease9
- off label use9
- dry skin8
- irritable bowel syndrome8
- polyarteritis nodosa8
- acne7
- application site pain7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 10 |
| 2012 | 7 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 9 |
| 2016 | 20 |
| 2017 | 21 |
| 2018 | 16 |
| 2019 | 14 |
| 2020 | 9 |
| 2021 | 8 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,997 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| polyarteritis nodosaSignal | 8 | 1805.0 | 914.0 | 12,503 |
| product physical consistency issueSignal | 11 | 258.6 | 146.1 | 2,566 |
| inflammatory bowel diseaseSignal | 18 | 239.3 | 154.7 | 4,031 |
| irritable bowel syndromeSignal | 8 | 48.5 | 24.7 | 326 |
| colitis ulcerativeSignal | 15 | 43.6 | 26.9 | 583 |
| application site painSignal | 7 | 41.3 | 20.0 | 236 |
| colitisSignal | 10 | 34.3 | 18.8 | 291 |
| acneSignal | 7 | 12.0 | 5.8 | 60 |
| depressionSignal | 14 | 8.0 | 4.8 | 80 |
| dry skinSignal | 8 | 7.8 | 4.0 | 41 |
| anxietySignal | 11 | 5.0 | 2.8 | 32 |
| rashSignal | 10 | 3.0 | 1.6 | 11 |
| drug ineffective | 19 | 1.9 | 1.2 | 7 |
| off label use | 9 | 1.3 | 0.7 | 0 |
| crohn^s disease | 9 | 0.0 | 0.0 | 1,043,313 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.